CAR-T Single-Cell Multi-omics Solution

Key Challenges in CAR-T Development

The questions that conventional assays cannot answer are exactly where single-cell omics creates value

Limited mechanistic basis for construct selection

Cytotoxicity and expansion alone cannot reveal the true impact of different co-stimulatory domains (CD28 vs 4-1BB) on intrinsic T-cell heterogeneity.

Surface-level product quality assessment

CAR positivity and viability do not capture core attributes that determine efficacy, such as functional subset composition and the proportion of progenitor exhausted cells.

Insufficient depth for post-treatment monitoring

Conventional flow cytometry cannot comprehensively capture in vivo exhaustion trajectories, memory differentiation, or immune microenvironment remodeling of CAR-T cells.

Relapse and resistance mechanisms are difficult to resolve

It often remains unclear whether treatment failure is driven by CAR-T exhaustion, target antigen loss, or immune suppression within the tumor microenvironment.

End-to-End Sequencing Strategy

R&D
Product Development
scRNA + scTCR + CITE-seq
QC
Manufacturing QC
scRNA + Flow Validation
Clinical
Clinical Monitoring
scRNA + Bulk TCR/BCR + scATAC
Relapse
Relapse / Resistance
scRNA + Spatial Transcriptomics + WES
Stage 1

Product Development: CAR Construct Optimization and Functional Validation

scRNA-seqscTCR-seqCITE-seq

What does each technology address?

scRNA-seq
Profiles the global transcriptomic impact of different CAR constructs (for example, CD28 versus 4-1BB co-stimulatory domains) on T cells, quantifies differences in effector, memory, and exhausted subsets, and provides a molecular basis for construct selection.
scTCR-seq
Tracks TCR clonotypes at single-cell resolution to assess whether a construct induces tonic signaling that leads to clonal skewing or abnormal clonal enrichment, an early warning signal of CAR design defects.
CITE-seq
Simultaneously measures the transcriptome and surface proteins (including CD4, CD8, PD-1, TIM-3, and LAG-3), closing the information gap between RNA and protein levels and enabling direct cross-validation with flow cytometry.

Why combine three omics layers in the R&D stage?

  • Samples at this stage are derived from in vitro cultured products, with adequate material and controllable conditions, making it the optimal window for comprehensive multi-omics characterization.
  • Joint analysis of three information layers (transcriptome + clonotype + protein) provides a complete evidence chain for evaluating construct performance.
  • The functional benchmarks and quality attributes defined at this stage directly support subsequent IND submissions.
Key Outputs: Optimal construct selection report · Functional phenotype benchmarks for T cells · Definition of product quality attributes · IND-enabling data package
Stage 2

Manufacturing QC: Final Product Release and Consistency Assessment

scRNA-seqFlow Validation

What does each technology address?

scRNA-seq
Performs deep characterization of the first several manufacturing batches, including the subset composition of CAR+ cells (Tscm, Tcm, Teff, Tex), CD4/CD8 ratios, and the proportion of progenitor exhausted cells, to establish product quality benchmarks.
Flow Validation
Translates key subset markers identified by scRNA-seq into flow cytometry panels suitable for routine testing (for example, Tcm: CD45RO+CCR7+CD62L+) and establishes executable release criteria.

Why is the QC stage streamlined to two technologies?

  • The core requirement in manufacturing is reproducibility and standardization, rather than exploratory multi-omics.
  • At this stage, scRNA-seq serves as a tool for establishing standards, using a limited number of batches for deep profiling to define release metrics.
  • Flow validation is the translational bridge from scRNA-seq, converting transcriptome-level subset discoveries into protein markers suitable for routine release testing.
  • scTCR-seq and CITE-seq are unnecessary here: the product is an ex vivo expanded and relatively homogeneous cell population, TCR diversity is not the central concern, and the protein-measurement role of CITE-seq can be fully replaced by flow cytometry.
Key Outputs: Established product release criteria · Batch-to-batch consistency assessment · Benchmark values for subset composition · Flow cytometry panel design
Stage 3

Clinical Monitoring: Pre-infusion Baseline and Post-infusion Longitudinal Tracking

scRNA-seqBulk TCR/BCRscATAC-seq

What does each technology address?

scRNA-seq
Longitudinally tracks in vivo expansion kinetics of CAR-T cells, the evolution of functional subsets (effector → memory → exhaustion), and global remodeling of the immune microenvironment, enabling identification of predictive biomarkers of response.
Bulk TCR/BCR
At one-fifth to one-tenth the cost of scTCR-seq, this approach tracks expansion and contraction dynamics of dominant clones as well as changes in clonal diversity across multi-timepoint, multi-patient cohort designs.
scATAC-seq
Reveals whether CAR-T exhaustion has become epigenetically fixed through chromatin remodeling, a critical determinant of reversibility that directly informs combination strategies with immune checkpoint blockade.

Why is the technology mix adjusted in the clinical stage?

  • Clinical samples, especially patient peripheral blood, are precious and require an optimal balance between cost efficiency and information yield.
  • Bulk TCR/BCR replaces scTCR-seq because the essential information for clonal tracking—dominant clones and diversity indices—can be effectively captured at much lower cost.
  • scATAC-seq is added because transcriptomic upregulation of exhaustion-associated genes alone cannot distinguish transient transcriptional activation from stable epigenetic fixation; scATAC-seq fills this critical gap.
  • CITE-seq is not repeated at this stage because flow cytometry can substitute for protein-level detection in clinical samples while consuming less material.
Key Outputs: CAR-T expansion and exhaustion kinetics · Clonal tracking atlas · Epigenetic mechanisms of exhaustion · Predictive biomarkers of efficacy
Stage 4

Relapse / Resistance Analysis: Mechanism Dissection and Therapeutic Strategy Optimization

scRNA-seqSpatial TranscriptomicsWES

What does each technology address?

scRNA-seq
Analyzes immunosuppressive networks in the post-relapse tumor microenvironment, including Treg enrichment, MDSC states, and newly emerging suppressive pathways, to identify resistance-associated cell subsets and pathway changes.
Spatial Transcriptomics
Reveals the actual infiltration pattern of CAR-T cells within tumor tissue and the spatial distribution of immunosuppressive regions, addressing a key question that scRNA-seq alone cannot answer: whether CAR-T cells truly penetrate the tumor core.
WES (Whole-Exome Sequencing)
Detects tumor genomic alterations such as target antigen loss (for example, CD19 mutation or deletion) and pathway mutations linked to tumor escape, including anti-apoptotic signaling changes, thereby explaining the genetic basis of resistance.

Why introduce spatial transcriptomics and WES in the resistance stage?

  • The central question in relapse or resistance is why treatment failed, which requires integrated answers across tumor biology, immunity, and genomics.
  • Spatial transcriptomics addresses a fundamental limitation of scRNA-seq: the loss of spatial context after tissue dissociation, which is particularly important in resistance analysis.
  • WES is essential for confirming target antigen loss—one of the most common mechanisms of CAR-T failure—at the genomic level.
  • Bulk TCR is no longer necessary at this stage because CAR-T cells may already be largely depleted at relapse, and the analytical focus should shift to tumor-intrinsic escape mechanisms.
Key Outputs: Validation of target antigen loss · Immunosuppressive network profiling in the TME · Tumor escape pathways · Design strategies for next-generation CAR constructs

Four-Stage Technology Matrix at a Glance

TechnologyR&DManufacturing QCClinical MonitoringRelapse / ResistanceCore Value
scRNA-seq✓✓✓✓Core platform across the full workflow, providing a transcriptomic landscape
scTCR-seq✓———Evaluates construct effects on clonality during the R&D stage
CITE-seq✓———Joint transcriptome-plus-protein validation in the R&D stage
Flow Validation—✓——Converts single-cell findings into routine release-testing standards
Bulk TCR/BCR——✓—Low-cost clonal tracking suitable for larger cohort designs
scATAC-seq——✓—Determines whether exhaustion has become epigenetically fixed
Spatial Transcriptomics———✓Reveals spatial patterns of tumor infiltration and immune suppression
WES———✓Detects target antigen loss and tumor-escape mutations
share
WeChat
Sina Weibo
QQ
QQ space
Douban
Baidu Post Bar
Tel：+86 15336557985
E-Mail：service@generulor.com
Micromessenger
Scan to consult
Linkedin
LIN HUABING
Teams：15022705442@163.com